Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neuro-ophthalmology

Treatment Options & Gene Therapy

At a Glance

While there is no cure for LHON, treatments like Idebenone (Raxone) help restore cellular energy production, and emerging gene therapies (Lumevoq) aim to repair the underlying genetic mutation. Starting treatment within 6 to 12 months of vision loss offers the best chance for visual recovery.

Managing Leber Hereditary Optic Neuropathy (LHON) has evolved significantly in recent years. While there is currently no cure, there are evidence-based treatments designed to bypass the mitochondrial “power failure” and, in some cases, replace the faulty genetic instructions entirely.

Supporting Energy Production: Idebenone

The current standard of care for LHON often involves Idebenone (brand name Raxone). This is a synthetic version of coenzyme Q10, a molecule your body uses naturally to create energy.

  • How it Works: In LHON, Complex I (the first part of your cell’s power plant) is broken. Idebenone acts like a biological bypass, shuttling electrons directly to the next part of the “power plant” (Complex III) so your cells can continue making ATP (energy) [1][2].
  • The Dose: The internationally recognized dose for LHON is 900 mg per day, which is taken as two 150 mg tablets three times a day, usually with meals, to ensure proper drug absorption [3][4].
  • The Timeline: Recovery takes time. Clinical consensus suggests that patients should stay on the medication for at least 1.5 to 2 years to see the full benefit [5][6]. Stopping the treatment too early may prevent potential visual recovery.
  • Safety: Idebenone is generally well-tolerated. Some patients may experience mild side effects like diarrhea, nausea, or a slight change in urine color [7].

Repairing the Source: Gene Therapy

A newer frontier in LHON treatment is gene therapy, specifically a product called lenadogene nolparvovec (Lumevoq). This treatment is currently designed specifically for people with the most common LHON mutation, m.11778G>A [8].

  • Administration: It is delivered via an intravitreal injection, which is a shot directly into the jelly-like part of the eye.
  • Clinical Trials (RESCUE, REVERSE, REFLECT): These large-scale studies showed that patients receiving gene therapy often had significant improvements in their Best-Corrected Visual Acuity (BCVA) compared to the natural history of the disease [8][9].
  • The “Transfer” Effect: One of the most surprising findings in these trials was that even when only one eye was injected, both eyes showed improvement [10]. Scientists believe the viral vector used to carry the healthy gene may travel from one eye to the other through the optic chiasm (where the optic nerves cross) [11][12].
  • Availability and Clinical Trials: It is critical to understand that lenadogene nolparvovec is largely an investigational therapy. Because it is still navigating regulatory approval, it may only be available through active clinical trials or specific early-access/compassionate use programs depending on where you live [8].

Factors for Success

Not everyone responds to treatment in the same way. Researchers have identified several factors that predict a better outcome for both Idebenone and gene therapy:

  1. Timing: Starting treatment as soon as possible after vision loss begins—ideally within the first 6 to 12 months—is associated with better results [13][14].
  2. Existing Nerve Health: Patients with thicker RNFL (nerve fibers) and GCL (cell bodies) on their OCT scans at the start of treatment tend to have better visual outcomes [15][16].
  3. Baseline Vision: Having slightly better vision at the time of the first injection or dose is also a positive predictor [15][13].

Important Note: Gene therapy is a rapidly advancing field. While current treatments focus on the m.11778G>A mutation, research is ongoing for other LHON mutations. Always discuss your specific genetic test results with a specialist to determine which trials or treatments you may be eligible for.

Return to Home Page

Common questions in this guide

Is there a cure for Leber Hereditary Optic Neuropathy (LHON)?
Currently, there is no cure for LHON, but there are evidence-based treatments designed to help restore vision. The standard of care often involves taking Idebenone, and investigational gene therapies are available through clinical trials.
How does Idebenone work for LHON?
Idebenone acts like a biological bypass in your cells' power plant. Because LHON causes a breakdown in part of the mitochondria, this medication shuttles electrons directly to the next working part so your cells can continue producing energy.
How long do I need to take Idebenone?
Clinical consensus suggests that patients should take Idebenone for at least 1.5 to 2 years to experience the maximum visual benefit. Stopping the medication too early may prevent or limit your potential visual recovery.
What is gene therapy for LHON?
Gene therapy is an advanced treatment delivered via an injection directly into the eye, designed to replace the faulty genetic instructions causing LHON. It is currently being investigated primarily for people with the most common LHON mutation, m.11778G>A.
Can treating one eye with gene therapy help the other eye?
Yes, clinical trials have shown a surprising transfer effect where injecting only one eye led to visual improvements in both eyes. Researchers believe the viral vector carrying the healthy gene may travel from one eye to the other through the optic chiasm.
What factors improve my chances of vision recovery with LHON treatments?
The most important factor is time; starting treatment within 6 to 12 months of initial vision loss yields the best results. Having a thicker retinal nerve fiber layer (RNFL) on your OCT scans before starting treatment also predicts better visual outcomes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my specific mutation, what is the best evidence-based treatment approach for me right now?
  2. 2.Am I eligible to enroll in any active clinical trials for gene therapy or other novel treatments?
  3. 3.If I start Idebenone, how often will we monitor my progress, and what are we looking for?
  4. 4.What are the potential risks or side effects of participating in a gene therapy trial?
  5. 5.What is my current RNFL and GCL thickness, and how do these numbers affect my potential for visual recovery?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    A viewpoint about Lenadogene nolparvovec failing to meet its primary endpoint even though it permanently corrects the m.11778G>A mutation causative of LHON.

    Panfoli I, Ravera S

    Eye (London, England) 2025; (39(11)):2110-2111 doi:10.1038/s41433-025-03856-5.

    PMID: 40394266
  2. 2

    Idebenone: When an antioxidant is not an antioxidant.

    Gueven N, Ravishankar P, Eri R, Rybalka E

    Redox biology 2021; (38()):101812 doi:10.1016/j.redox.2020.101812.

    PMID: 33254077
  3. 3

    A challenging differential diagnosis - Leber's Hereditary Optic Neuropathy.

    Iorga RE, Munteanu-Dănulescu RS, Danielescu C

    Romanian journal of ophthalmology 2024; (68(1)):65-71 doi:10.22336/rjo.2024.13.

    PMID: 38617721
  4. 4

    Assessment of the Idebenone Effect on LHON Eyes Requires High-quality Studies.

    Finsterer J

    Current eye research 2020; (45(11)):1451-1452 doi:10.1080/02713683.2020.1748660.

    PMID: 32250653
  5. 5

    Evaluation of Visual and Optical Coherence Tomography Outcomes in Patients with Leber's Hereditary Optic Neuropathy Treated with Idebenone.

    Iorga RE, Moraru AD, Munteanu-Dănulescu RS, et al.

    Life (Basel, Switzerland) 2025; (15(8)) doi:10.3390/life15081172.

    PMID: 40868820
  6. 6

    Leber's hereditary optic neuropathy: course of disease in consideration of idebenone treatment and type of mutation.

    Tonagel F, Wilhelm H, Richter P, Kelbsch C

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2021; (259(4)):1009-1013 doi:10.1007/s00417-020-05045-4.

    PMID: 33337510
  7. 7

    International Consensus Statement on the Clinical and Therapeutic Management of Leber Hereditary Optic Neuropathy.

    Carelli V, Carbonelli M, de Coo IF, et al.

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2017; (37(4)):371-381 doi:10.1097/WNO.0000000000000570.

    PMID: 28991104
  8. 8

    Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy.

    Newman NJ, Yu-Wai-Man P, Subramanian PS, et al.

    Brain : a journal of neurology 2023; (146(4)):1328-1341 doi:10.1093/brain/awac421.

    PMID: 36350566
  9. 9

    Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE Study.

    Biousse V, Newman NJ, Yu-Wai-Man P, et al.

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2021; (41(3)):309-315 doi:10.1097/WNO.0000000000001367.

    PMID: 34415265
  10. 10

    Leber hereditary optic neuropathy gene therapy.

    Lam BL

    Current opinion in ophthalmology 2024; (35(3)):244-251 doi:10.1097/ICU.0000000000001028.

    PMID: 38117686
  11. 11

    Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates.

    Calkins DJ, Yu-Wai-Man P, Newman NJ, et al.

    Molecular therapy. Methods & clinical development 2021; (23()):307-318 doi:10.1016/j.omtm.2021.09.013.

    PMID: 34729378
  12. 12

    Ocular stress enhances contralateral transfer of lenadogene nolparvovec gene therapy through astrocyte networks.

    McGrady NR, Boal AM, Risner ML, et al.

    Molecular therapy : the journal of the American Society of Gene Therapy 2023; (31(7)):2005-2013 doi:10.1016/j.ymthe.2023.03.035.

    PMID: 37016579
  13. 13

    Factors associated with rapid improvement in visual acuity in patients with Leber's hereditary optic neuropathy after gene therapy.

    Liu HL, Yuan JJ, Zhang Y, et al.

    Acta ophthalmologica 2020; (98(6)):e730-e733 doi:10.1111/aos.14379.

    PMID: 32096343
  14. 14

    Therapeutic benefit of idebenone in Leber hereditary optic neuropathy: a systematic review and meta-analysis.

    Ribeiro PVZ, Pari Mitre L, Gauza MM, et al.

    Ophthalmic genetics 2025; (46(6)):517-522 doi:10.1080/13816810.2025.2521647.

    PMID: 40653811
  15. 15

    Predictors of Final Visual Outcome in Patients With Leber Hereditary Optic Neuropathy Treated With Lenadogene Nolparvovec Gene Therapy.

    Sergott RC, Carelli V, Newman NJ, et al.

    Investigative ophthalmology & visual science 2025; (66(9)):42 doi:10.1167/iovs.66.9.42.

    PMID: 40662892
  16. 16

    Quantitative assessment of retinal microvasculature using optical coherence tomography angiography and correlation with visual acuity in leber's hereditary optic neuropathy.

    Zhao Q, Ma Y, Zhou X, et al.

    International ophthalmology 2025; (45(1)):376 doi:10.1007/s10792-025-03619-x.

    PMID: 40913669

This page provides educational information about LHON treatments and investigational gene therapies. Always consult your neuro-ophthalmologist or genetic specialist for medical advice and clinical trial eligibility.

Get notified when new evidence is published on Leber hereditary optic neuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.